News OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-17 pm EDT			5-day change	1st Jan Change
1.52 ^USD	-1.94%		+4.11%	-14.12%

Mar. 22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
Mar. 22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OKYO Pharma Announces Participation in May 2024 Investor Conferences	May. 08	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	Apr. 30	AQ
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	Apr. 08	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	Apr. 02	AQ
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	Mar. 22	MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22	AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	Mar. 20	CI
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	Mar. 20	AQ
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Sector Update: Health Care	Feb. 09	MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	Feb. 09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09	CI
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09	AQ
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	Jan. 31	AQ
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	Jan. 31	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	Jan. 08	CI
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	Jan. 08	AQ
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	Jan. 05	AQ
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	Dec. 18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Summary

Filters